By The Pulseline News Desk
Sri Lanka’s public healthcare system is facing growing concern over the availability of essential medicines, following official data that reveals significant shortages of vital and priority drugs across the government health network.
According to information updated on June 16, 2026, through the SWASTHA Medicine Stock Management System, a substantial number of medicines managed by the Medical Supply Division (MSD) are either out of stock or at risk of running out in the coming months.
The figures, highlighted by Health Professionals Association President Ravi Kumudesh, paint a troubling picture for a healthcare system that serves millions of patients through government hospitals and clinics.
Life-saving meds unavailable
Among the most concerning findings is the complete absence of two out of 13 vital medicine items at the MSD level. While the percentage may appear small, health experts warn that vital medicines are often life-saving drugs required for emergency and critical care.
Any disruption in their availability can directly affect patient outcomes, particularly in intensive care units, emergency departments, and specialised treatment centres.
“Even a single missing vital medicine can have serious consequences for patient care,” health sector observers note.
Priority meds also in short supply
The shortages extend beyond vital medicines. Official data reportedly shows that 137 out of 618 priority medicine items – more than 22 percent – are currently unavailable at the MSD level.
Priority medicines are widely used treatments required for managing common illnesses, chronic diseases, and routine hospital care. Their absence can lead to treatment delays, increased costs, and additional pressure on healthcare providers.
The figures suggest that nearly one in every five priority medicines is currently facing supply challenges.
Stocks running dangerously low
Equally concerning is the status of existing stocks.
According to reports, the data indicates that 116 priority medicine items have only one month’s supply remaining, while another 59 items have stocks sufficient for just one to two months.
In total, 175 priority medicine items – representing 28.3 percent of all priority medicines managed by the MSD – are classified as being at high risk of depletion in the near future.
Healthcare professionals warn that such low stock levels leave little room to respond to unexpected increases in demand, supply disruptions, or procurement delays.
Questions over procurement and supply chains
The revelations have prompted renewed scrutiny of Sri Lanka’s pharmaceutical procurement system.
Health sector stakeholders are calling on authorities to explain the underlying causes of the shortages, including whether delays in tender processes, procurement bottlenecks, funding constraints, or international supply chain disruptions have contributed to the situation.
There are also growing concerns regarding contingency measures for medicines that are already critically low in stock.
Questions remain as to whether hospitals have begun substituting alternative medications, postponing certain treatments, or relying on emergency procurement measures to bridge supply gaps.
Importance of buffer stocks
International best practices recommend maintaining adequate buffer stocks of essential medicines to ensure uninterrupted patient care during emergencies and supply disruptions.
Experts say the current stock situation underscores the importance of long-term planning, forecasting, and inventory management within the national healthcare system.
Maintaining sufficient reserves is particularly important in a country where the public health sector remains the primary source of medical treatment for a large segment of the population.
Patient safety at stake
For patients, medicine shortages can translate into delayed treatment, interrupted therapy, and uncertainty regarding access to critical healthcare services.
Medical professionals caution that persistent shortages can erode public confidence in the healthcare system and place additional burdens on doctors, pharmacists, and hospital administrators who must find alternatives when standard treatments are unavailable.
As concerns continue to mount, healthcare advocates are urging greater transparency from authorities regarding current stock levels, procurement timelines, and recovery plans.
The latest figures serve as a stark reminder that a reliable pharmaceutical supply chain is not merely an administrative requirement but a fundamental pillar of patient safety and public health. Ensuring uninterrupted access to essential medicines, experts say, must remain a national priority.
Leave a comment